1. Show article details.

    Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

    GlobeNewswire – 8:00 AM ET 11/17/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing.

  2. Show article details.

    BRIEF-Assembly Biosciences, Door Pharmaceuticals Sign Collaboration, Option Agreement To Develop Novel Class Of HBV Core Protein Modulators

    Reuters – 8:48 AM ET 11/16/2020

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES AND DOOR PHARMACEUTICALS SIGN COLLABORATION AND OPTION AGREEMENT TO DEVELOP A NOVEL CLASS OF HBV CORE PROTEIN MODULATORS Source text for Eikon: Further company coverage:

  3. Show article details.

    Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators

    GlobeNewswire – 8:00 AM ET 11/16/2020

    Assembly Biosciences (ASMB), Inc.  and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus core protein modulators.

  4. Show article details.

    Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™

    GlobeNewswire – 8:00 AM ET 11/13/2020

    - Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline - SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases assoc...

  5. Show article details.

    Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:30 PM ET 11/06/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020.

  6. Show article details.

    BRIEF-Assembly Biosciences Q3 Earnings Per Share Estimate $-0.75 -- Refinitiv Ibes Data

    Reuters – 4:35 PM ET 11/05/2020

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE. * Q3 LOSS PER SHARE $0.09. * Q3 EARNINGS PER SHARE ESTIMATE $-0.75 -- REFINITIV IBES DATA. * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $237.9 MILLION AS OF SEPTEMBER 30, 2020.

  7. Show article details.

    BRIEF-Assembly Biosciences Provides Update On The Ongoing Phase 2 Extension Study Of Vebicorvir In Patients With Chronic Hepatitis B Virus Infection

    Reuters – 4:03 PM ET 11/05/2020

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES PROVIDES UPDATE ON THE ONGOING PHASE 2 EXTENSION STUDY OF VEBICORVIR IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. * Assembly Biosciences Inc (ASMB) - STUDY HAS NOT ACHIEVED MEANINGFUL SVR RATES AS 39 OF 41 PATIENTS HAVE NOW RELAPSED.

  8. Show article details.

    Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update

    GlobeNewswire – 4:02 PM ET 11/05/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today reported financial results and a business update for the third quarter ended September 30, 2020.

  9. Show article details.

    Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

    GlobeNewswire – 4:01 PM ET 11/05/2020

    - HBV field’s first core inhibitor combination study to assess off-treatment response has not achieved a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program remains on track to initiate in H1 2021 for chronic suppressive therapy -- Assembly Bio to host conference call today at 5:00 p.m. ET - SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 -- Assembly Bioscie...

  10. Show article details.

    Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™

    GlobeNewswire – 8:00 AM ET 11/02/2020

    - Four posters, including two late breaking, will include new clinical and preclinical data on Assembly Bio’s hepatitis B virus core inhibitor portfolio SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 -- Assembly Biosciences (ASMB), Inc. , a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced that data...

  11. Show article details.

    Assembly Biosciences Appoints Gina Consylman to Board of Directors

    GlobeNewswire – 8:00 AM ET 10/20/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors.

  12. Show article details.

    Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award

    GlobeNewswire – 8:00 AM ET 10/15/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award.

  13. Show article details.

    Assembly Biosciences Announces October Conference Participation

    GlobeNewswire – 7:30 AM ET 10/05/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020Panel: What are the virological and immunological gaps that need to be addressed?

  14. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:30 PM ET 10/02/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Company’s common stock with an exercise price of $17.29 per share, the closing price of Assembly’s common stock ...

  15. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:30 PM ET 09/04/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Company’s common stock with an exercise price of $20.14 per share, the closing price of Assembly’s common stock...

  16. Show article details.

    Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020

    GlobeNewswire – 6:00 AM ET 08/28/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Co...

  17. Show article details.

    Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

    GlobeNewswire – 8:00 AM ET 08/27/2020

    SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 -- Assembly Biosciences, Inc. (ASMB) and Arbutus Biopharma Corporation (ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-ca...

  18. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:30 PM ET 08/07/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock ...

  19. Show article details.

    Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

    GlobeNewswire – 4:05 PM ET 08/05/2020

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today reported financial results and recent highlights for the second quarter ended June 30, 2020.

  20. Show article details.

    Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

    GlobeNewswire – 6:30 AM ET 07/20/2020

    -- BeiGene (BGNE) acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million upfront payment and is eligible to receive up to $500 million in potential development, regulatory, and sales milestone payments plus royalties on product sales ---- Assembly to host webcast and conference call today at 8:30 am ET -- SOUTH SAN...

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    05

    ASMB announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.